Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the role of immunotherapy for patients with head and neck cancer.
- Dr. Lopes on Immunotherapy in Head and Neck Cancer ( Download)
- Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC ( Download)
- Dr. Lee on the Impact of Immunotherapy in Head and Neck Cancer ( Download)
- Dr. Weiss on Next Steps for Immunotherapy in Head and Neck Cancer ( Download)
- Dr. Ferris on Pembrolizumab and Nivolumab in Head and Neck Cancer ( Download)
- Dr. Succaria on Combination Immunotherapy in Head and Neck Cancer ( Download)
- Dr. Bauml on Immunotherapy Combinations in Head and Neck Cancer ( Download)
- Dr. Burtness on Frontline Immunotherapy in Head and Neck Cancer ( Download)
- Nivolumab-Related Efficacy and Toxicity in HNSCC Patients ( Download)
- Lung cancer: Clinical insights into key research | Gilberto Lopes ( Download)
- Dr. Gilberto Lopes, Sylvester Comprehensive Cancer Center, Miami, USA ( Download)
- Dr. Lopes Discusses the Importance of Addressing Financial Toxicity in Lung Cancer ( Download)
- ASCO 2018 Head and Neck Roundtable Advances in Immunotherapy in Head and Neck Cancer ( Download)
- KEYNOTE Trial Data: Pembrolizumab’s Role in NSCLC ( Download)
- Pembrolizumab works better than chemotherapy alone as initial treatment for NSCLC ( Download)
